Evidence map›Paper›PMID 24572175›Full record

ReviewImmunology letters2014

Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.

E Sally Ward, Ramraj Velmurugan, Raimund J Ober

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

E Sally WardDepartment of Immunology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. Electronic address: sally.ward@utsouthwestern.edu.
Ramraj VelmuruganDepartment of Immunology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Biomedical Engineering Graduate Program, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas TX 75390, USA. Electronic address: ramraj.velmurugan@utsouthwestern.edu.
Raimund J OberDepartment of Immunology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of Electrical Engineering, University of Texas at Dallas, Richardson, TX 75080, USA. Electronic address: raimund.ober@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · US

Funding

High accuracy quantum dot tracking in live cellsR01GM085575 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI OBER, RAIMUND J · 2008 to 2016
$2.5M
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseasesR01AR056478 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI WARD, ELIZABETH SALLY · 2008 to 2012
$1.9M
NIAMS NIH HHS R01 AR056478NIAMS NIH HHS R01 AR 56478NIGMS NIH HHS R01 GM085575NIGMS NIH HHS R01 GM 85575
6 · The paper itself

Abstract

The role of FcRn in regulating antibody levels and transport in the body is well documented. The use of fluorescence microscopy to investigate the subcellular trafficking behavior of FcRn and its IgG ligand has led to insight into the function of this receptor, including the identification of new intracellular pathways. The inhibition of FcRn using engineered antibodies that bind to this receptor with increased affinity through their Fc region can be exploited to treat antibody mediated autoimmunity. The efficacy of this approach in mouse models of arthritis and multiple sclerosis has been demonstrated. Finally, the cross-species difference between mouse and man for FcRn-IgG interactions needs to be considered when engineering antibodies for improved activities in FcRn-mediated functions.

Indexed as

AnimalsAntibodiesArthritisDisease Models, AnimalGene ExpressionHumansImmunization, PassiveImmunoglobulin GMiceMice, TransgenicMolecular ImagingMultiple SclerosisProtein BindingProtein EngineeringReceptors, FcAntibodiesImmunoglobulin GReceptors, FcAntibody engineeringAntibody pharmacokineticsAutoimmunityFcRnImmunoglobulin GLive-imaging microscopy

Identifiers

PMID24572175
PMCPMC4058420
OpenAlexW1976400144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.